Scienture Holdings, Inc.
NNASDAQ:SCNXCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Shankar Hariharan
- Full Time Employees
- 9
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- 20 Austin Boulevard Commack NY United States 11725
- IPO Date
- Feb 6, 2014
- CIK
- 0001382574
- Website
- scienture.com
- Similar Companies
- Business
- Scienture Holdings, Inc. (NASDAQ:SCNX) operates as a holding company for pharmaceutical operating companies focused on developing, commercializing, and distributing novel specialty pharmaceutical products to address unmet needs in central nervous system and cardiovascular diseases in the United States. The company conducts operations through its Scienture, LLC subsidiary, which researches and develops branded products including SCN-102, an oral liquid formulation of losartan potassium in phase 1 for hypertension, diabetic nephropathy, and stroke risk reduction; SCN-104, a multi-dose dihydroergotamine mesylate injection pen for acute migraine treatment; SCN-106, a thrombolytic agent for thrombosis; and SCN-107, a long-acting non-opioid analgesic injection for postsurgical pain; through Integra Pharma Solutions for wholesale of licensed pharmaceutical brands, generics, and non-drug products; and previously through divested healthcare IT and wholesale units. Products target patients, physicians, caregivers, hospitals, clinics, and pharmacies across therapeutic areas such as hypertension, migraine, pain, and thrombosis, with geographic focus in the United States; founded in 2010 and headquartered in Tampa, Florida. In September 2024, the company rebranded from TRxADE Health, Inc., changed its ticker from MEDS to SCNX, and completed a business combination with Scienture, Inc. valued at $103 million; in Q1 2024 sold TRxADE Inc. assets for $22.5 million; in April 2025 divested legacy subsidiaries Integra Pharma Solutions, Bonum Health, and Softell to Tollo Health for $5 million to streamline as a pure-play specialty pharma entity; secured $1.2 million in bridge funding toward $3 million in July 2025 and priced a $3.9 million registered direct offering; launched Arbli (losartan potassium) as the first FDA-approved ready-to-use liquid available via major U.S. wholesalers, with multiple GPO agreements and PBM-led rebate deals expanding access to over 2,500 institutions in the $256 million losartan market; and fully repaid outstanding debentures to strengthen its balance sheet.
Company News
SCIENTURE Issues Shareholder Letter Highlighting Sequential Revenue Growth, Two FDA-Approved Commercial Products, and Continued Progress Toward Profitability in 2027
SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth
SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals
Scienture Holdings, Inc. Announces Reverse Stock Split
SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner
SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026
SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance
SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray
SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers
SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers
SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide
SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team
SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC
SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041
SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline
SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041
SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041
Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead